Trevi Therapeutics develops nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia

Sectors
Healthcare
Life Sciences
First Invested
2017
Growth
Company Status
IPO/Public
NASDAQ: TRVI
Board Members
Edward Mathers